| Authors: |
Strønen E; Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. K. G. Jebsen Centers for Cancer Immunotherapy and for Inflammation Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Toebes M; Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands., Kelderman S; Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands., van Buuren MM; Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands., Yang W; Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. K. G. Jebsen Centers for Cancer Immunotherapy and for Inflammation Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., van Rooij N; Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands., Donia M; Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark., Böschen ML; Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. K. G. Jebsen Centers for Cancer Immunotherapy and for Inflammation Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Lund-Johansen F; K. G. Jebsen Centers for Cancer Immunotherapy and for Inflammation Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. Department of Immunology and Transfusion Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway., Olweus J; Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. K. G. Jebsen Centers for Cancer Immunotherapy and for Inflammation Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. johanna.olweus@medisin.uio.no t.schumacher@nki.nl., Schumacher TN; Division of Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands. johanna.olweus@medisin.uio.no t.schumacher@nki.nl. |